Last reviewed · How we verify
Adara 5% Cream Canada
Adara 5% Cream is a topical corticosteroid that reduces inflammation and suppresses immune responses in the skin.
Adara 5% Cream is a topical corticosteroid that reduces inflammation and suppresses immune responses in the skin. Used for Inflammatory skin conditions (e.g., atopic dermatitis, contact dermatitis, eczema).
At a glance
| Generic name | Adara 5% Cream Canada |
|---|---|
| Sponsor | Apotex Inc. |
| Drug class | Topical corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
As a topical corticosteroid formulation, Adara works by binding to glucocorticoid receptors in skin cells, thereby reducing inflammatory cytokine production and suppressing local immune cell activity. This mechanism alleviates symptoms associated with inflammatory skin conditions such as dermatitis, eczema, and other corticosteroid-responsive dermatological disorders.
Approved indications
- Inflammatory skin conditions (e.g., atopic dermatitis, contact dermatitis, eczema)
Common side effects
- Skin atrophy
- Burning or stinging at application site
- Pruritus
- Folliculitis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adara 5% Cream Canada CI brief — competitive landscape report
- Adara 5% Cream Canada updates RSS · CI watch RSS
- Apotex Inc. portfolio CI